EyeDNA Therapeutics Announces Positive 24-month Data Presented at ARVO from Ongoing Phase I/II Trial of HORA-PDE6b Gene Therapy in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
GlobeNewswire
Clinically meaningful benefit in visual functions and good safety profile of HORA-PDE6b is confirmed at 24-month..